Management of chemotherapy-associated febrile neutropenia

The development of febrile neutropenia during a course of chemotherapy is not only a life-threatening complication, it can also lead to a decision to reduce chemotherapy intensity in subsequent treatment cycles, thus putting patient outcomes at risk. Although there are strategies available for the primary prevention of febrile neutropenia, these are not widely used in the UK management of breast cancer. It is, therefore, paramount to have a well thought out and rigorously implemented care protocol for febrile neutropenia, involving patients, family/carers and health-care professionals in both primary and secondary care, to ensure early detection and effective management

Chemo-, regio-, and diastereoselective synthesis of functionalized cyclopropanes by cyclization of dilithiated nitriles with epibromohydrin

[GRAPHICS] The cyclization of 1,1-dianions with epibromohydrin results in chemo-, regio-, and diastereoselective formation of functionalized hydroxymethyl cyclopropanes

Regio- and diastereoselective synthesis of lissoclinolide analogues by Lewis acid catalyzed cyclization of the first 1,5-bis(trimethylsilyloxy)-1,3,5-hexatrienes with oxalyl chloride

The Lewis acid catalyzed cyclization of 1,5-bis(trimethylsilyloxy)-1,3,5-hexatrienes with oxalyl chloride resulted in formation of polyunsaturated butenolides

Bacterial Infection Prevention After Hematopoietic Cell Transplantation

WoSScopu

Methodology for clinical trials involving patients with cancer who have febrile neutropenia: Updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies

SCOPUS: ar.jinfo:eu-repo/semantics/publishe